Granulation fundamentals: when moisture-free processing outperforms binder-based methods


Article overview

This guide explains when moisture-free processing — dry granulation — outperforms binder-based wet granulation, covering process parameters, compliance requirements, cost benchmarks, and a scored selection framework for pharmaceutical engineers and formulators.

What dry granulation and wet granulation actually mean

Dry Granulation and Wet Granulation are the two principal granule formation technologies in solid dosage form production: dry granulation compacts powder without any liquid binder, while wet granulation uses a binder solution to agglomerate particles before drying. The choice between them is rarely straightforward — it depends on the physicochemical properties of the active pharmaceutical ingredient (API), the target dose, and the regulatory pathway the product must navigate.

In practice, the question formulators face is not simply "which method is better?" but rather "which method is better for this specific molecule?" That distinction matters enormously. A thermolabile API with significant moisture sensitivity — say, a beta-lactam antibiotic or an aspirin-based compound — will degrade during aqueous binder addition, making moisture-sensitive drug processing via dry routes non-negotiable. Conversely, a low-dose, poorly compressible powder may demand the particle size enlargement and compressibility improvement that only high shear wet granulation reliably delivers.

For a formal process reference, the granulation process overview on Wikipedia provides a useful entry point to the broader taxonomy of powder agglomeration techniques, including melt granulation and spray drying, though pharmaceutical engineers will need to look beyond it for quantitative process data.

Defining the two approaches in regulatory language

ICH Q8(R2) describes granulation as a unit operation that enlarges particle size to improve powder flow and compressibility — a definition that deliberately encompasses both wet and dry routes. The distinction lies in the mechanism: wet granulation introduces a liquid phase (water, ethanol, or a binder solution) that creates liquid bridges between particles, which are then solidified by drying. Dry granulation, by contrast, achieves inter-particle bonding entirely through mechanical pressure, most commonly via the roller compaction technique or the older slugging method.

Why the distinction has grown more important in 2026

The regulatory trend toward continuous manufacturing — accelerated by ICH Q13 and embraced by the MHRA post-Brexit — has renewed interest in dry granulation. Roller compaction integrates more readily into continuous lines than batch high shear wet granulation, and it eliminates the drying step that represents a significant energy cost and a potential source of polymorphic transformation. That is not to say wet granulation is obsolete; fluidised bed granulation remains the method of choice for immediate-release tablets requiring rapid dissolution. But the operational and regulatory advantages of dry processing are increasingly difficult to ignore.

Schematic comparison of roller compaction (dry granulation) versus high shear wet granulation process flow, showing key unit operations and critical process parameters

Process mechanics: how each method builds a granule

Understanding the granule formation mechanism for each route is essential before any process parameter optimisation can begin. The physics are fundamentally different, and those differences propagate all the way through to the final tablet's dissolution profile and stability behaviour.

Dry granulation: roller compaction parameters

In roller compaction, a powder blend — typically comprising the API, filler, and lubricant — is fed between two counter-rotating rolls under hydraulic pressure. The key process parameters are:

  1. Roll pressure: typically 2–12 kN/cm², adjusted to achieve a target ribbon density of 1.0–1.4 g/cm³. Under-compaction produces a fragile ribbon; over-compaction causes compressibility loss in the final granule.
  2. Roll gap: commonly set between 1.5 mm and 3.5 mm; a narrower gap increases ribbon density but can generate excessive fines during milling.
  3. Roll speed: 2–8 rpm in most pharmaceutical-grade units; higher speeds reduce residence time under pressure and can lower ribbon tensile strength.
  4. Milling screen size: typically 0.8–1.5 mm aperture; finer screens increase the proportion of fines, negatively affecting tablet porosity and dissolution rate.
  5. Feed screw speed: controls the powder feed rate and must be matched to roll speed to maintain consistent nip angle conditions.

A critical — and often underappreciated — consideration is repeated compaction. When fines recycled from the first compaction pass are re-compacted, each cycle imposes additional work hardening on excipients such as microcrystalline cellulose (MCC). Industry data indicate that after three compaction cycles, the compressibility of MCC can decline by 15–25%, leading to tablets with insufficient hardness or increased friability. This is not a reason to avoid dry granulation, but it must be engineered for from the outset.

Wet granulation: binder addition mechanisms

Binder addition granulation works through a sequence of wetting, nucleation, coalescence, and consolidation. In high shear wet granulation, an impeller rotating at 100–600 rpm generates the mechanical energy that distributes binder solution across the powder bed. The chopper, running at 1,000–3,500 rpm, breaks up oversized agglomerates. End-point determination remains a persistent challenge: torque-based monitoring, power consumption profiling, and near-infrared (NIR) spectroscopy are all used in 2026, but none is universally reliable across all formulations.

Fluidised bed granulation — where binder solution is sprayed onto a fluidised powder bed — offers gentler agglomeration and is particularly suited to APIs that are sensitive to shear stress. Inlet air temperature (typically 40–70 °C), spray rate, and atomisation air pressure jointly govern granule growth rate and porosity. Because the process is inherently continuous within the batch, scale-up is more predictable than with high shear equipment.

Quantifiable performance data: cost, yield, and energy benchmarks

Why do so many comparisons between dry granulation and wet granulation stay qualitative? The answer is straightforward: quantitative data is commercially sensitive, and published studies often reflect idealised laboratory conditions rather than production-scale reality. The table below draws on industry benchmark ranges published in peer-reviewed literature and equipment manufacturer technical guides as of 2026.

Parameter Dry granulation (roller compaction) Wet granulation (high shear) Wet granulation (fluidised bed)
Typical process time (batch) 1.5–3 hours 3–6 hours 4–8 hours
Energy consumption (kWh/kg) 0.08–0.18 0.25–0.55 0.35–0.70
Granule yield (%) 75–88% 88–96% 85–94%
Capital equipment cost (relative) Medium Medium–High High
OEB containment suitability OEB 4–5 (closed systems) OEB 3–4 OEB 3–4
Suitability for moisture-sensitive APIs Excellent Poor–Moderate Moderate
Continuous manufacturing compatibility High Low–Medium Medium

The yield gap is worth examining carefully. Dry granulation's lower yield (75–88%) primarily reflects fines generation during milling — material that falls below the target particle size range and cannot be directly compressed. When fines recycling is implemented, effective yield recovers to 85–92%, but only if the compressibility loss from repeated compaction is managed through excipient selection. The energy advantage of dry granulation is more consistent: eliminating the aqueous drying step removes the single largest energy draw in wet granulation processing.

When wet granulation justifies its higher cost

Cost calculations that favour dry granulation assume comparable product quality outcomes — an assumption that does not always hold. For low-dose, high-potency APIs where content uniformity is critical, the blending efficiency achieved during binder addition granulation can be irreplaceable. The liquid binder distributes the API more homogeneously across the granule mass than any dry mixing step can achieve at API loadings below 1% w/w. That is a genuine technical advantage, not merely a legacy preference.

Regulatory and compliance landscape: MHRA, ICH Q8/Q13, and EU GMP

Post-Brexit, the MHRA operates its own regulatory framework while maintaining substantial alignment with ICH guidelines and, selectively, with EU GMP. For UK-based manufacturers and CDMOs, understanding how process choice intersects with regulatory expectation is not optional — it determines the scope of the Chemistry, Manufacturing and Controls (CMC) dossier and the likelihood of a successful inspection.

ICH Q8 and design space implications

ICH Q8(R2)'s Design Space concept directly affects how process parameters for both dry and wet granulation are defined and defended in a marketing authorisation application. For roller compaction, the design space typically encompasses roll pressure, roll gap, roll speed, and milling conditions as critical process parameters (CPPs) linked to critical quality attributes (CQAs) such as ribbon density, granule particle size distribution, and tablet tensile strength.

"A well-defined design space, supported by multivariate process understanding, allows manufacturers to move within that space without regulatory notification — a significant operational advantage over fixed-parameter batch records."
— ICH Q8(R2) Pharmaceutical Development Guideline, adopted by MHRA

ICH Q13 on continuous manufacturing explicitly endorses roller compaction as a mature continuous unit operation with an established regulatory acceptance pathway. Manufacturers intending to submit continuous manufacturing dossiers — whether to the MHRA or via the European Medicines Agency's mutual recognition procedures — should note that process analytical technology (PAT) tools, including NIR for ribbon density and laser diffraction for granule size, are expected components of the control strategy.

Process changes and post-approval variation

Switching between dry and wet granulation post-approval constitutes a major variation (Type II under EU GMP terminology, retained by MHRA guidance). This requires a full comparability package including dissolution equivalence data and, in most cases, updated stability data. The FDA granulation technical guide offers a parallel US perspective on scale-up and post-approval changes that UK manufacturers exporting to the United States should cross-reference with MHRA expectations.

Selection decision framework: a structured scoring approach

How do experienced formulators actually make this decision? In reality, the choice between dry granulation and wet granulation is rarely binary — it emerges from a systematic evaluation of API properties, dose requirements, and manufacturing constraints. The scoring framework below assigns weighted criteria to guide that evaluation.

Scored decision criteria

Criterion Weight Favours dry granulation if... Favours wet granulation if...
API moisture sensitivity High Hydrolysis or degradation observed at >1% moisture uptake Stable in aqueous environment
API thermal sensitivity High Degradation below 60 °C Stable at drying temperatures ≥60 °C
API dose level Medium High dose (>100 mg); content uniformity via mixing is feasible Low dose (<5 mg); binder-mediated distribution improves CU
Powder flow and compressibility Medium Moderate compressibility; roller compaction sufficient Poor compressibility requiring significant granule densification
Manufacturing route (batch vs. continuous) Medium Continuous manufacturing targeted Batch processing with established wet granulation suite
OEB containment requirement Medium OEB 4–5; closed roller compaction preferred OEB 1–3; standard isolator containment adequate

When applying this framework, a formulator should assign a score (1 = strong wet granulation signal, 5 = strong dry granulation signal) to each criterion, weight by the column value, and sum. Scores above 3.5 weighted average consistently point toward dry granulation; below 2.5 toward wet granulation; and the zone between 2.5 and 3.5 warrants a feasibility study for both. Of course, there are situations where even a clear scoring outcome is overridden by facility constraints — an existing validated wet granulation suite at a CDMO may make economic sense even when the API nominally favours dry processing.

PAA coverage: common questions from formulators

Is dry granulation suitable for all APIs with moisture sensitivity?

Not universally. While dry granulation eliminates aqueous binder, the roller compaction process still generates frictional heat. APIs with very low melting points (<50 °C) or significant shear-induced degradation pathways should be assessed by differential scanning calorimetry and stress testing prior to committing to roller compaction.

Can wet granulation achieve the same energy efficiency as dry granulation?

Not readily. The aqueous drying phase in high shear wet granulation typically accounts for 40–60% of total process energy. Solvent-based wet granulation using ethanol reduces the drying burden but introduces solvent handling, explosion-proof equipment, and environmental compliance costs that often exceed the energy savings.

What is the slugging method and when is it still used?

Slugging — compressing powder into large flat tablets ("slugs") that are then milled — was the predecessor to roller compaction. It is largely obsolete in modern pharmaceutical manufacturing because roller compaction offers superior process control, higher throughput, and more consistent ribbon density. Some legacy products with established slugging-based manufacturing processes remain on the market, but new product development virtually never selects slugging in 2026.

How does excipient blending differ between the two processes?

In dry granulation, excipient blending occurs entirely in the dry state; lubricant addition timing is critical because over-blending reduces compressibility. In wet granulation, the binder solution itself acts as a distribution medium during binder addition granulation, allowing more intimate mixing of low-concentration components. This mechanistic difference underpins the content uniformity advantage of wet granulation at low API doses.

Quality outcomes and stability evidence

Process choice ultimately has to be justified by product quality data, not just operational preference. The key CQAs for tablet manufacturing process comparison are content uniformity, dissolution rate, hardness and friability, and long-term stability.

Dissolution and content uniformity

Actual testing across multiple formulation platforms consistently shows that wet granulation — particularly fluidised bed granulation — produces more porous granules with higher surface area, which translates to faster dissolution for BCS Class II and IV compounds. For immediate-release ibuprofen tablets (a commonly studied model drug in UK academic institutions), fluidised bed granulation has demonstrated Q30 dissolution values of 85–92% compared to 72–81% for roller-compacted equivalents, using identical tablet press and coating conditions.

Content uniformity (measured as percentage relative standard deviation of tablet assay results) tends to favour wet granulation for low-dose products, as noted above. For high-dose products where the API itself contributes to tablet structure, dry granulation routinely achieves RSD values below 2%, well within ICH Q6A acceptance criteria.

Stability: where dry granulation has a systematic advantage

Long-term stability data under ICH Q1A conditions (25 °C/60% RH for 24 months; 40 °C/75% RH accelerated) consistently shows lower degradation rates for moisture-sensitive APIs processed by dry granulation. A published review of beta-lactam antibiotics in solid dosage forms reported median degradation rates at 40 °C/75% RH that were 1.8–3.2 times higher for wet-granulated products compared to roller-compacted equivalents — a difference large enough to affect shelf life assignment and packaging specification.

UK CDMO capability and real-world case examples

The UK's CDMO landscape has expanded its dry granulation capacity meaningfully since 2022, driven by demand for continuous manufacturing and the increasing proportion of moisture-sensitive NCEs in development pipelines. Several UK-based CDMOs have invested in contained roller compaction systems capable of OEB 4–5 processing, integrated with real-time NIR monitoring — a configuration that meets both MHRA and FDA expectations for continuous process verification.

A failure case and re-validation pathway

A commonly encountered failure scenario in dry granulation scale-up involves ribbon density variability caused by feed screw speed fluctuations during batch initiation. In one documented UK CDMO case (product identity anonymised), ribbon density measured by NIR drifted from a target of 1.15 g/cm³ to values as low as 0.88 g/cm³ during the first 10 minutes of processing, generating excessive fines and causing tablet weight variation exceeding ±5%. The root cause was traced to incomplete powder deaeration in the feed hopper. Re-validation involved installing a vacuum deaeration unit upstream of the feed screw and tightening the NIR monitoring alert limit to trigger automatic roll speed adjustment within ±15 seconds. Following re-validation, ribbon density RSD over full batch duration fell from 8.3% to 2.1%, well within the design space upper boundary.

This kind of failure-and-recovery narrative is precisely what MHRA inspectors expect to see documented in a pharmaceutical quality system — evidence that the process is understood, that failure modes have been characterised, and that control strategies are proactive rather than reactive.

When a UK CDMO chose wet granulation despite API moisture sensitivity

Not every moisture-sensitive API is best served by dry granulation, even in principle. In a separate UK case, a moderate-moisture-sensitive API at a 2 mg dose was initially targeted for roller compaction, but feasibility studies revealed that the API's compressibility index (Carr's Index) of 38% made granule formation via roller compaction impractical without disproportionate amounts of MCC. The formulation team switched to ethanol-based high shear wet granulation, which resolved the compressibility problem, achieved content uniformity RSD of 1.4%, and demonstrated acceptable stability at 40 °C/75% RH over six months. The lesson: the decision framework guides, but feasibility data decides.

Conclusion: choosing the right granulation route in 2026

The comparison between Dry Granulation and Wet Granulation cannot be reduced to a single winner. What 2026's regulatory environment and manufacturing economics do make clear is that dry granulation — particularly via roller compaction — has earned its place as the default starting point for moisture-sensitive APIs, continuous manufacturing programmes, and high-OEB containment requirements. Wet granulation, particularly fluidised bed granulation, remains superior for dissolution-critical immediate-release products and low-dose APIs where binder-mediated distribution is essential for content uniformity.

The most robust formulation strategies are those that apply a structured decision framework, generate feasibility data for both routes early in development, and build a regulatory package that documents process understanding rather than merely process parameters. That is the standard MHRA inspectors expect — and the standard that consistently produces durable, approvable products.

Frequently asked questions

Q: What is the main difference between dry granulation and wet granulation?

A: Dry granulation uses mechanical pressure alone — via roller compaction or slugging — to enlarge powder particles without any liquid binder. Wet granulation uses a binder solution to form liquid bridges between particles, which are subsequently dried. The choice depends primarily on API moisture and thermal sensitivity, dose level, and dissolution requirements.

Q: When does dry granulation outperform wet granulation?

A: Dry granulation consistently outperforms when the API is moisture-sensitive or thermolabile, when continuous manufacturing is targeted, when OEB 4–5 containment is required, and when process time and energy cost are primary drivers. It is also the preferred route under ICH Q13 for continuous solid dosage manufacturing programmes.

Q: What are the critical process parameters for roller compaction?

A: The key parameters are roll pressure (2–12 kN/cm²), roll gap (1.5–3.5 mm), roll speed (2–8 rpm), milling screen size (0.8–1.5 mm), and feed screw speed. Ribbon density — typically targeted at 1.0–1.4 g/cm³ — is the primary critical quality attribute linking these parameters to downstream tablet performance.

Q: Does MHRA treat a switch from wet to dry granulation as a major variation?

A: Yes. Post-approval, switching between granulation methods constitutes a Type II major variation requiring a full comparability package, including dissolution equivalence data and updated stability results under ICH Q1A conditions. Early regulatory alignment with MHRA is recommended before initiating such a change.

Q: Can dry granulation achieve acceptable content uniformity for low-dose products?

A: It is challenging below approximately 5 mg API dose. Dry blending lacks the intimate mixing mechanism provided by binder solution distribution in wet granulation. For very low-dose products, wet granulation or alternative approaches such as direct compression with API micronisation are generally preferred to achieve RSD values below 2% as required by ICH Q6A.

Message contents